EVUSHELD is a combination of two long-acting monoclonal antibodies (LAAB) and is the only antibody therapy authorized in the U.S. for pre-exposure prophylactic (preventive) use against COVID-19 in immunocompromised patients. EVUSHELD therapy is administered in two quick intramuscular doses and provides up to a 77% reduction in the risk of COVID-19 infection for 6 months after administration.